Sanofi-Aventis’ Semuloparin To Face Skeptical FDA At ODAC Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency questions the true benefit of the drug in preventing venous thromboembolism in certain cancer patients, even with a more limited population than the sponsor originally asked for.